NCT05322083View on ClinicalTrials.gov

HIV A6 Genome In ART Unsuccessful Patients On DOR

UnknownOBSERVATIONAL

Enrollment

60

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

May 31, 2023

Study Completion Date

January 31, 2024

Conditions

Virus-HIV

Interventions

DRUG

Doravirine

Doravirine will be given to patients after failure on the first NNRTI regimen.

Sponsors

Collaborators (1)

MSD Pharmaceuticals LLC

All Listed Sponsors

collaborator

MSD Pharmaceuticals LLC

INDUSTRY

lead

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

OTHER

NCT05322083 - HIV A6 Genome In ART Unsuccessful Patients On DOR | Biotech Hunter | Biotech Hunter